Dignity Health unveiled results from a randomized controlled study which demonstrated that the use of digital health technology improved asthma control. The study, “Effectiveness of Population Health Management Using the Propeller Health Asthma Platform: A Randomized Clinical Trial,” was recently published in the Journal of Allergy and Clinical Immunology: In Practice.
The Propeller Health Asthma Platform uses sensors, mobile apps, and analytics to monitor short-acting β-agonist (SABA) and inhaled corticosteroid use in real-time. The platform provides detailed information about patterns of medication use and notifications about patients with worsening asthma control.
“The research demonstrates that the benefits of telehealth go beyond monitoring medication adherence, but can also identify patterns of risk and impairment. This additional information may allow more timely interventions and enhanced asthma management,” Dr. Rajan Merchant, the principal study investigator and physician at Dignity Health’s Woodland Clinic Medical Group, said in a statement. “Although additional study efforts are needed, digital health is promising to help improve care and asthma control.”
The study included 495 adults and children, and has found that the total amount of SABA use and the total number of days when SABA was needed, was lower in the group using the Propeller Health Asthma Platform compared to the patients receiving routine care. Moreover, a significantly greater increase in the Asthma Control Test was demonstrated in adults with uncontrolled asthma in the intervention group compared to adults with uncontrolled asthma under routine care.
David Van Sickle, CEO of Propeller Health, is obviously “very pleased” with the results. “Our partnership with Dignity Health is important as we continue to advance innovation in chronic respiratory disease management and improve patients’ quality of life,” he added.